Extended-release Sodium Oxybate in Children
Key facts
- Where
- Redwood City, United StatesSee the site
- Phase
- Phase 2
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 7 and 17 years old?
Source: NCT06809803, who can take part
Where in United States
- Stanford UniversityRedwood City, United StatesContact: Miran ChoTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Stanford University
- Trial code
- NCT06809803
- Record updated
- 6 November 2025
- Original description
The main objectives of this study are to determine the treatment preferences of children with narcolepsy type 1 between Extended-release sodium oxybate and Non-extended-release oxybates (Sodium oxybate or a medication with the combination of Calcium, magnesium, potassium, and sodium oxybates). The study will also assess the safety, convenience, and tolerability of Extended-release sodium oxybate. Additionally, the researchers aim to assess how well Extended-release sodium oxybate works in treating narcolepsy type 1.Read full original descriptionShow less
Safety, Convenience, and Tolerability of a Nightly Single Oral Dose of Extended-release Sodium Oxybate in Children
The main objectives of this study are to determine the treatment preferences of children with narcolepsy type 1 between Extended-release sodium oxybate and Non-extended-release oxybates (Sodium oxybate or a medication with the combination of Calcium, magnesium, potassium, and sodium oxybates). The study will also assess the safety, convenience, and tolerability of Extended-release sodium oxybate. Additionally, the researchers aim to assess how well Extended-release sodium oxybate works in treating narcolepsy type 1.
Inclusion: Participants must be under the care of a doctor at the Stanford Sleep Clinic; Participants must have a documented diagnosis of narcolepsy type 1 shown by sleepiness and either: a spinal fluid marker for narcolepsy (hypocretin-1) at a specific level, or a history of sudden loss of muscle control (cataplexy), or a particular genetic marker for narcolepsy, or a sleep study showing a specific sleep pattern for narcolepsy; Parent(s), or guardian(s) have signed a consent form and the child must agree to participate; Participants are on a stable dose of medications.
Exclusion: Currently having a problem with illegal drug use; Participants who have any of the following conditions will not be included in the study; Uncontrolled mental health problems; Uncontrolled sleep problems that lead to sleepiness; Currently having thought about ending one's life or sadness or loss of interest; Currently pregnant.